NF-κB and its downstream cytokines, IL-18 and IL-10, may serve as inflammation-driven, noninvasive biomarkers for prostate cancer diagnosis, staging, and risk stratification, particularly in populations exposed to environmental factors.
Dwivedi et al. (2026) studied this question.